{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1890865118073617153.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Motte-Vincent, Pauline"}],"foaf:familyName":[{"@value":"Motte-Vincent"}],"foaf:givenName":[{"@value":"Pauline"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1870865118073616640","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1016/s2213-2600(21)00099-0"},{"@type":"PMID","@value":"33676590"},{"@type":"HANDLE","@value":"20.500.12530/59486"},{"@type":"HANDLE","@value":"20.500.11768/118815"},{"@type":"HANDLE","@value":"2434/821467"},{"@type":"HANDLE","@value":"11380/1280422"},{"@type":"HANDLE","@value":"11381/2893979"}],"notation":[{"@value":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"OPENAIRE","@value":"doi_dedup___::86e19d3078b0e1d6c3cb7bbbbc2f83f0_USddj7Jo7lDcpsNw7AY0OGoY5nh"}]}